Colony Group’s Ocular Therapeutix OCUL Stock Holding History

Colony Group’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-24,000	Closed	-$240K	–	843
2021 Q3	$240K	Hold	24,000	–	–	﹤0.01%	754
2021 Q2	$340K	Hold	24,000	–	–	0.01%	609
2021 Q1	$394K	Hold	24,000	–	–	0.01%	587
2020 Q4	$497K	Hold	24,000	–	–	0.01%	505
2020 Q3	$183K	Hold	24,000	–	–	﹤0.01%	699
2020 Q2	$200K	Hold	24,000	–	–	0.01%	656
2020 Q1	$119K	Hold	24,000	–	–	﹤0.01%	645
2019 Q4	$95K	Hold	24,000	–	–	﹤0.01%	729
2019 Q3	$73K	Hold	24,000	–	–	﹤0.01%	688
2019 Q2	$106K	Hold	24,000	–	–	﹤0.01%	707
2019 Q1	$95K	Buy	+24,000	New	+$96.5K	﹤0.01%	619

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Colony Group's OCUL Position: Q4 2021 in Review

Colony Group sold out of Ocular Therapeutix (OCUL) in Q4 2021, closing a stake of 24,000 shares — an estimated $240K sold.

Colony Group first reported a position in OCUL in Q1 2019 and held it in 11 quarters. The position peaked at $497K in Q4 2020. 140 funds tracked by Wall St. Rank hold OCUL as of Q4 2021.

Colony Group reported no remaining Ocular Therapeutix position as of Q4 2021 after selling out during the quarter.
Colony Group sold 24,000 Ocular Therapeutix shares in Q4 2021, an estimated $240K.
Colony Group first reported a position in Ocular Therapeutix in Q1 2019 and held it in 11 quarters.
Colony Group's Ocular Therapeutix position peaked at $497K in Q4 2020.
140 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2021.

Based on Colony Group's 13F filing for Q4 2021, filed 15 Feb 2022.